Table of Contents
JERUSALEM — Teva Pharmaceutical Industries Ltd. has launched entecavir tablets (0.5 mg and 1 mg), an antiviral medication, in the United States.
Teva said Thursday that its product is the generic equivalent of Baraclude tablets, marketed by Bristol-Myers Squibb.
In addition, Teva said that because it was the first to file, its Baraclude generic is eligible for 180 days of marketing exclusivity.
Baraclude tablets 0.5 mg and 1 mg, used to treat chronic hepatitis B virus, had annual U.S. sales of about $328 million through June 2014, according to IMS Health data cited by Teva.
